A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects With Chronic Cough

Trial Profile

A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects With Chronic Cough

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Gefapixant (Primary)
  • Indications Cough
  • Focus Proof of concept; Therapeutic Use
  • Acronyms EPICC
  • Sponsors Afferent Pharmaceuticals
  • Most Recent Events

    • 10 Dec 2015 Results published early online in the Lancet
    • 25 Nov 2014 Results published in an Afferent Pharmaceuticals media release and also published online in The Lancet.
    • 31 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top